PolyPid Ltd. (PYPD) Q4 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Greetings and welcome to Polypeed's fourth quarter and full year 2025 conference call. At this time, participants are in a listen-only mode. As a reminder, this call is recorded. And I would now like to introduce your host for today's conference, Yuda Liebler from ARCS Investor Relations. Mr Liebler, you may begin. Thank you, Operator, and thank you all for joining PolyPID's fourth quarter and full year 2025 earnings conference call. Joining me on the call today will be Dikla Chachkes-Akselblad, Chief Executive Officer of PolyPID, Jonny Misalawin, PolyPID's Chief Financial Officer, and Ori Warschawski, Chief Operating Officer US of PolyPID. Earlier today, PolyPID released its financial results for the three and 12 months ending December 31st, 2025. A copy of the press release is available in the investor section on the company's website at www.polypid.com. I'd like to remind you that on this call, management will make forward-looking statements within the meaning of the Federal Securities Law. For example, management is making forward-looking statements when it discusses the company's regulatory strategy and the anticipated timing and structure of the planned new drug application or NDA submission for DPLEX 100, including the rolling submission, the potential regulatory and commercial pathways for D-Flex 100, the company's ongoing partnership discussions, commercialization readiness, transition from a primarily R&D and clinically focused organization into one that is preparing for commercialization, the potential for 2026 to be a transformative year for the company, benefits and advantages of D-Flex 100, that Kinatrix represents a broader long-term opportunity for PolyPID, and the expectation that current cash resources will be sufficient to fund operations into the ...